Faculty Opinions recommendation of European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology.

Author(s):  
Wolfram Hoetzenecker
2016 ◽  
Vol 15 (2) ◽  
pp. 228-241 ◽  
Author(s):  
Alexander Enk ◽  
Eva Hadaschik ◽  
Rüdiger Eming ◽  
Gerhard Fierlbeck ◽  
Lars French ◽  
...  

2016 ◽  
Vol 30 (10) ◽  
pp. 1657-1669 ◽  
Author(s):  
A.H. Enk ◽  
E.N. Hadaschik ◽  
R. Eming ◽  
G. Fierlbeck ◽  
L.E. French ◽  
...  

2020 ◽  
Vol 18 (12) ◽  
pp. 1394-1403
Author(s):  
Johanna Stoevesandt ◽  
Johanna Heitmann ◽  
Matthias Goebeler ◽  
Sandrine Benoit

2018 ◽  
Vol 4 (1) ◽  
pp. 205521731875811
Author(s):  
Yuki Matsumoto ◽  
Mario Tsuchiya ◽  
Shakespear Norshalena ◽  
Chikako Kaneko ◽  
Jin Kubo ◽  
...  

A 26-year-old, 17-week pregnant woman developed aquaporin-4-IgG-positive severe longitudinally extensive transverse myelitis during the course of disseminated herpes zoster and became quadriparetic. She was unresponsive to high-dose intravenous methylprednisolone but became able to walk without assistance after intravenous immunoglobulin. One and a half months later, left optic neuritis developed but her vision improved with intravenous immunoglobulin. The only sequela was left T5 girdle sensation, and she delivered a healthy baby. Intravenous immunoglobulin may be a rescue therapy in aquaporin-4-IgG-positive neuromyelitis optica attacks in pregnant women, especially those with severe infections.


Sign in / Sign up

Export Citation Format

Share Document